
30 Years on, Voyager's B'Elanna Split Episode Remains Fascinatingly Fraught
Star Trek has always been fascinated with the idea of characters pulled between two worlds. Spock's exploration of his human heritage, Worf's status on TNG as an early example of post-peace Klingon integration with the Federation, even Sisko's position as a Starfleet officer thrust into the simultaneous roles of guiding diplomat, military leader, and spiritual emissary—time and time again the series has been drawn to this character archetype across ideas of race and status.
Early Star Trek Voyager was no exception with its interest in B'Elanna Torres, one of the show's early breakout characters. The Maquis rebel turned chief engineer who embodied this trope not just through her own journey as an ex-guerrilla, but also as a half-Klingon woman—and the show's first real attempt to explore that latter, 30 years ago today in 'Faces,' had to tread fertile, yet highly contentious ground.
'Faces' was the 14th episode of Voyager's debut season, and saw the return of the Vidiians, a race of aliens forced to harvest organs and body parts from other species to try and avoid being ravaged by a horrifying plague. Having captured a handful of Voyager crew while they were on an away mission, B'Elanna included, a Vidiian scientist eager to explore the potential impact of regenerative elements in Klingon DNA in battling that plague uses his people's advanced medical technology to reach an unorthodox conclusion: split B'Elanna into two people. Completely separated down to the genetic level into separate human and Klingon individuals (both played by Torres actress Roxann Dawson, with the help of photo double Joy Kilpatrick), both B'Elannas ultimately have to overcome their differences to find a way to escape the Vidiians alongside their fellow captured crewmates.
The idea makes literal Star Trek's aforementioned fascination with characters who struggle to reconcile being from two very different backgrounds, but by making B'Elanna's first real exploration of her biracial identity on the show so literal, 'Faces' has to skirt some pretty wild lines that it can never really quite interrogate. Much of the conflict between the human B'Elanna and the Klingon B'Elanna is derived from what is ultimately presented by the episode as genetically derived traits. Human B'Elanna is physically and emotionally weaker, repeatedly incapacitated by fear as she struggles to adapt to being held prisoner by the Vidiians. Klingon B'Elanna, meanwhile, plays up the established Klingon caricature of violence and anger issues, an underlying arrogance that sees her seek conflict before anything else.
It's made especially fraught given the post-TNG re-imagining of the Klingons away from their original (and similarly racially fraught!) depictions and toward a race of almost exclusively dark-skinned humanoids, alongside other Afro-inspired traits like textured hair. The image of a slight light-skinned human B'Elanna (for what it's worth, Dawson is of Puerto Rican descent) cowering in the presence of her aggressively framed, dark-skinned Klingon self is brought up time and time again in 'Faces,' as the two argue with each other over being 'cursed' with the negative traits of the other, human B'Elanna lamenting her Klingon temper as being the reason she ultimately left Starfleet Academy. Even though by the end of 'Faces' the two come to an understanding, and the Klingon B'Elanna is allowed to sacrifice herself to protect the human B'Elanna she had admonished as her lesser, it's still presented in more of a way of the noble savage trope than it is a particularly enlightened re-imagining of their bond.
But while 'Faces' ultimately concludes that the two B'Elannas work better together, it doesn't exactly interrogate the racialized element at play between them in presenting her internal conflict over her biracial identity as an external one. Even the climax of the episode, when B'Elanna has reached that aforementioned understanding with her Klingon self, handles it in a compromised manner—her re-embrace of her Klingon side is done as much out of any kind of acceptance as it is the fact that she's told that she has to re-integrate with her Klingon DNA, without which she won't survive. The episode's final moments are intriguingly framed: the still-human-appearing B'Elanna tells Chakotay as she sits in Voyager's sickbay waiting to undergo surgery that while she now appreciates and admires aspects of her Klingon self, she is also reckoning with the fact that she will fight that version of herself for the rest of her life, before stroking her smooth forehead in solitude for one last time before the physical reminder of her internal struggle returns.
For much of the rest of Voyager, the series' exploration of B'Elanna's racial identity will be explored through her damaged relationship with her Klingon mother, rather than her own internal attitudes to being part-Klingon. That is, with one significant, equally wild exception: the season seven episode 'Lineage,' which sees a newly pregnant B'Elanna attempt to genetically alter her child in-utero to ensure they are born fully human.
It's fascinating that much of the show's exploration of her identity is bookended with these episodes that are broadly in conversation with each other, and not necessarily in the best of ways. 'Lineage,' while providing a level of understanding for B'Elanna's choices, is at least much more definitive in its view that her apprehensive view of being part-Klingon is misguided, and her actions in the episode are equivocally in the wrong. Perhaps then, 'Faces' walked so it could run—and provide a chance to do a bit more right by a character Voyager had been deeply interested in from its earliest beginnings.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Sir Rod Stewart 'devastated' after cancelling more US concerts as he recovers from flu
Sir Rod Stewart says he is devastated to have to cancel a series of US concerts, blaming lingering flu for the decision. It affects four shows in Nevada, along with a further two in California, which he plans to reschedule. They were due to take place over the next eight days. "So sorry my friends. I'm devastated and sincerely apologise for any inconvenience to my fans. I'll be back on stage and will see you soon," he wrote in a message on Instagram. , 80, has been struggling to recover from flu and this week had already cancelled two concerts at Caesars Palace, Las Vegas. On Wednesday, he disclosed that his doctor had "ordered" him to take "a bit more rest". The star is in the midst of his epic One Last Time Tour. Sir Rod, who was recently put on vocal rest, is due to later this month. In May, he was presented with a lifetime achievement award at the American Music Awards (AMAs). In a sign of how seriously the singer takes his health, last month he was also spotted in Italy attempting to avoid conversations to preserve his voice. He wore a message attached to a lanyard which read: "Sorry. Cannot talk. Having vocal rest." In 2024, he promised he would not retire but confirmed his 2025 European and North American shows would bring an end to his "large-scale world tours". Read more from Sky News: The performer, best known for songs including Da Ya Think I'm Sexy?, Every Beat Of My Heart, and Maggie May, said he plans to focus on more intimate venues instead. Sir Rod has faced other health challenges in the past. In May 2000, he was diagnosed with thyroid cancer and had surgery. In 2017, he underwent successful treatment for prostate cancer.
Yahoo
26 minutes ago
- Yahoo
Miley Cyrus Explains How She Used to Hide All of the Money She Spent on Drugs from Her Accountant
Miley Cyrus recalls the days of hiding her drug purchases from those around her The former Disney star visited The Ringer's Every Single Album podcast where she discussed her drug use during Miley Cyrus & Her Dead Petz era She has also openly discussed her sobriety journeyMiley Cyrus is opening up about her past drug use — and how she used to keep it a secret from those around her, specifically her accountant. The music artist, 32, got candid while taking a deep dive into where she was mentally for each of her albums like Bangerz and Endless Summer Vacation, for the Friday, June 6 episode of The Ringer's Every Single Album podcast. During their discussion of her 2015 album, Miley Cyrus & Her Dead Petz, the former Disney star revealed where some of her money went without her accountant's knowledge. 'The drugs were the biggest cost, which to hide those from my accountant, we called them vintage clothes,' Cyrus said. The 'Flowers' singer continued, 'And so she would get these checks. That happens on touring all the time.' Cyrus said over time her accountant would wonder about the "vintage clothes" costs but she always made sure to keep her purchases discreet. 'And every time she saw me, she'd be like, 'Where's that, like, $15,000 original John Lennon T-shirt that you bought?' It's like, 'Oh, it's upstairs,' ' she said. 'We just really want to protect it. It's really delicate. The fabric got to take care of it. So I bought a lot of vintage clothes that year,' Cyrus added. Continuing to reflect on Miley Cyrus & Her Dead Petz, the 'We Can't Stop' singer admitted she's grateful for how far she's come since that period in her life. 'I'm so glad I survived that time in my life," Cyrus said. "I would definitely not encourage anyone else to go this hard, but the fact that I got through it, I'm very glad I got to do it.' Cyrus has been open about her sobriety throughout the passing years. In a 2017 interview with Billboard, she said she was 'evolving' after giving up marijuana. 'I haven't smoked weed in three weeks, which is the longest I've ever [gone without it],' she said at the time. 'I'm not doing drugs, I'm not drinking, I'm completely clean right now! That was just something that I wanted to do.' She later spoke to Rolling Stone for the magazine's January 2021 cover story after she "fell off" and started drinking during the pandemic. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "[I] haven't done drugs in years. Honestly, I never try to, again, be a fortune-teller. I try to not be naive," Cyrus said at the time. "Things f—--- happen. But from sitting here with you right now, I would say it would have to be a cold day in hell for me to relapse on drugs." If you or someone you know is struggling with substance abuse, please contact the SAMHSA helpline at 1-800-662-HELP. Read the original article on People


Health Line
29 minutes ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.